Diagnostyka (DIA.WA) Stock Price

Diagnostyka Price

CLOSED
148.40
​
Market closed

Over the last 4 years Diagnostyka grew revenue by 6.5% annually, reaching 2.34 B PLN. Earnings per share have declined at 18.0% per year over the last 4 years. For Diagnostyka, the net margin of 10.7% is down versus 30.7% a few years ago. At today's price the dividend yield works out to roughly 2.23%. The payout ratio is around 44% of earnings. The consensus 12-month price target for Diagnostyka is 215.73 PLN, about 45.4% above where the stock trades today. Of 10 analysts, 7 rate the stock a buy — an overall Buy consensus.

Diagnostyka stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnostyka business model & stock analysis

Diagnostyka SA generates revenue through its network of 180 laboratories and 1,100 Sampling Labs across Poland, offering over 3,000 test types including hematology, infection diagnostics, allergology, and hormonal diagnostics. The company provides both routine and specialist laboratory services, with tests available with or without a physician's referral, catering to individual patients and healthcare providers. Its specialization in molecular biology, autoimmune diagnostics, and blood collection drives demand from private individuals seeking direct access to medical analysis without a doctor's prescription. The firm's revenue model relies on a comprehensive service chain from biological material collection and transportation to final analysis results, serving a broad customer base including patients, clinics, and hospitals. With a focus on accessible diagnostics, Diagnostyka SA expands its market reach through its extensive lab network, enabling widespread availability of medical testing services throughout Poland. The company's ability to deliver specialized tests like molecular biology and autoimmune diagnostics differentiates its offerings in the healthcare sector.

Frequently asked questions about Diagnostyka

Analysts currently set an average price target of 213.35 PLN for the Diagnostyka stock (median: 215.73 PLN), implying +46.0 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the Diagnostyka stock: 7 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Diagnostyka to generate revenue of 2.74 B PLN and earnings per share of 8.32 PLN.

Converted at the current exchange rate, the Diagnostyka share trades at 33.59 EUR (148.40 PLN).

The expected revenue of Diagnostyka is 2.74 B PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Diagnostyka is 280.80 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Diagnostyka is currently 17.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Diagnostyka stock.

The price-to-sales ratio (P/S) of Diagnostyka is currently 1.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Diagnostyka stock.

The Eulerpool Quality Score for Diagnostyka is 7/10.

The ISIN of Diagnostyka is PLDGNST00012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Diagnostyka is DIA.WA. The ticker symbol is used to trade Diagnostyka shares on the stock exchange.

Fair ValueTerminal
157.30 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website diag.pl
Country
Poland
Currency
PLN
Initial public offering
Feb 7, 2025
ISIN
PLDGNST00012
Cusip
X1876Y116
Market capitalization
5.01 B PLNMid Cap
52-Week Range
PEG
1.43
P/E ratio
P/Ee 2026
17.84
P/Ee 2027
14.55
P/Ee 2028
10.12
P/Ee 2029
10.60
P/Ee 2030
—
P/S
P/Se
1.83
EV/EBIT
14.65
P/B Ratio
9.48
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
21.76 %
Dividend
Dividend yield
2.23 %
Est. Dividend Yield
2.23 %
Payout Ratio
44.41 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
19.00 %
Last updated Nov 3, 2026, 3:39 AM

Diagnostyka Peer Group